全文获取类型
收费全文 | 542126篇 |
免费 | 49993篇 |
国内免费 | 32052篇 |
专业分类
耳鼻咽喉 | 5318篇 |
儿科学 | 7939篇 |
妇产科学 | 6600篇 |
基础医学 | 45653篇 |
口腔科学 | 10297篇 |
临床医学 | 66135篇 |
内科学 | 64277篇 |
皮肤病学 | 6191篇 |
神经病学 | 19828篇 |
特种医学 | 20992篇 |
外国民族医学 | 96篇 |
外科学 | 51560篇 |
综合类 | 119295篇 |
现状与发展 | 118篇 |
一般理论 | 45篇 |
预防医学 | 51080篇 |
眼科学 | 9990篇 |
药学 | 61406篇 |
670篇 | |
中国医学 | 42880篇 |
肿瘤学 | 33801篇 |
出版年
2024年 | 2312篇 |
2023年 | 7444篇 |
2022年 | 18597篇 |
2021年 | 23662篇 |
2020年 | 19084篇 |
2019年 | 13153篇 |
2018年 | 14249篇 |
2017年 | 15520篇 |
2016年 | 13233篇 |
2015年 | 22076篇 |
2014年 | 27898篇 |
2013年 | 31515篇 |
2012年 | 45601篇 |
2011年 | 48842篇 |
2010年 | 38442篇 |
2009年 | 33484篇 |
2008年 | 37426篇 |
2007年 | 36287篇 |
2006年 | 33020篇 |
2005年 | 28429篇 |
2004年 | 19767篇 |
2003年 | 16646篇 |
2002年 | 13414篇 |
2001年 | 12357篇 |
2000年 | 10675篇 |
1999年 | 8066篇 |
1998年 | 3970篇 |
1997年 | 3951篇 |
1996年 | 3070篇 |
1995年 | 2788篇 |
1994年 | 2458篇 |
1993年 | 1619篇 |
1992年 | 2392篇 |
1991年 | 2098篇 |
1990年 | 1743篇 |
1989年 | 1511篇 |
1988年 | 1298篇 |
1987年 | 1232篇 |
1986年 | 984篇 |
1985年 | 795篇 |
1984年 | 520篇 |
1983年 | 415篇 |
1982年 | 250篇 |
1981年 | 201篇 |
1980年 | 192篇 |
1979年 | 243篇 |
1978年 | 141篇 |
1977年 | 112篇 |
1976年 | 98篇 |
1974年 | 116篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
中药生产过程质量控制关键技术研究进展 总被引:10,自引:8,他引:2
中医药发展已上升到国家战略层面,在医药行业贯彻实施"中国制造2025"战略的新形势下,中药生产过程质量控制是中药工业需要加快突破的关键领域之一。对中药生产过程质量控制领域在工艺设计、分析检测、过程建模、制造装备等方面的关键共性问题进行解析,综述了中药生产过程质量控制体系中工艺过程理解、生产过程实时分析方法开发、过程控制策略建立3个方面的研究进展;并结合企业研究实践,介绍了质量源于设计(quality by design,Qb D)、过程分析技术(process analytical technology,PAT)、实验设计(design of experiment,DOE)、多变量统计分析等关键技术在上述3个研究方向中的应用进展,分析了实际工业应用的难点问题并对其应用前景进行展望,旨在为中药企业应用和提升生产过程质量控制技术提供参考。 相似文献
2.
3.
目的:探讨保留肾脏的输尿管部分切除术治疗原发性输尿管癌的长期疗效。方法:回顾性分析1999年3月~2013年2月行保留肾脏的输尿管部分切除术的31例输尿管癌患者临床资料:12例患者行输尿管膀胱再植术,19例行输尿管端端吻合术。随访14~171个月,观察术后尿路肿瘤复发率、患者总体生存率、肿瘤分期及病理分级方面分层生存率等情况。结果:术后尿路肿瘤复发率为19.35%(6/31);总体5年及10年生存率分别为77.41%、58.64%;低肿瘤分期组5年及10年生存率均为86.67%,高肿瘤分期组5年及10年生存率分别为74.93%和54.29%;低病理分级组5年及10年生存率均为76.00%,高病理分级组5年及10年生存率分别为78.26%和48.83%。结论:在严密随访下,输尿管部分切除术可以有效治疗低分期、低分级输尿管癌。 相似文献
4.
5.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis 下载免费PDF全文
6.
7.
8.
9.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
10.
Xiujuan Tian Zhiying Chen Shaomin Shi Xianwen Wang Wanli Wang Ning Li Jing Wang 《Medicine》2015,94(37)
Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is one of the most leading causes of cancers worldwide. Due to a low 5-year survival rate, highly effective methods for the early detection of OSCC are totally needed. MicroRNAs (miRNAs), as promising biomarkers, can bring insights into tumorigenesis of oral cancers. However, studies on the accuracy of miRNAs detection in OSCC have inconsistent conclusions, leading us to conduct this meta-analysis. The aim of this study was to systematically review the articles investigating the diagnostic value of miRNAs in OSCC.The PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), Web of Science were searched (updated to June 11th, 2015) to identify all articles evaluating the diagnostic yield of miRNAs for OSCC. The pooled sensitivity, specificity, and other diagnostic parameters were used to assess the performance of miRNAs assays on OSCC detection. Statistical analysis was conducted by employing the R software.The present meta-analysis comprised 23 studies from 10 articles, including 598 OSCC patients and 320 healthy individuals, available for analysis. The summary receiver operator characteristic (SROC) curve was plotted. Meanwhile, the pooled diagnostic parameters and the area under curve (AUC) were calculated based on all included studies. The pooled diagnostic parameters calculated from all 23 studies were as follows: pooled sensitivity of 0.759 (95% CI: 0.701–0.809), pooled specificity of 0.773 (95% CI: 0.713–0.823) and AUC of 0.832, which indicates a relatively high diagnostic accuracy of miRNAs in differentiating OSCC patients from healthy controls. Meanwhile, In addition, subgroup analyses were conducted to access the heterogeneity between studies, which is based on specimen (serum/plasma/blood/saliva/ tissue) and ethnicity (Asian/Caucasian).In summary, our meta-analysis suggests that miRNAs might be used in noninvasive screening tests for OSCC, which needs further large-scale studies to be validated. 相似文献